DNLI
Price
$14.41
Change
-$0.04 (-0.28%)
Updated
Jun 26, 01:15 PM (EDT)
Capitalization
2.1B
35 days until earnings call
PRTA
Price
$5.93
Change
-$0.06 (-1.00%)
Updated
Jun 26, 01:35 PM (EDT)
Capitalization
322.42M
42 days until earnings call
Interact to see
Advertisement

DNLI vs PRTA

Header iconDNLI vs PRTA Comparison
Open Charts DNLI vs PRTABanner chart's image
Denali Therapeutics
Price$14.41
Change-$0.04 (-0.28%)
Volume$200
Capitalization2.1B
Prothena
Price$5.93
Change-$0.06 (-1.00%)
Volume$200
Capitalization322.42M
DNLI vs PRTA Comparison Chart in %
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. PRTA commentary
Jun 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Buy and PRTA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 26, 2025
Stock price -- (DNLI: $14.45 vs. PRTA: $5.99)
Brand notoriety: DNLI and PRTA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 79% vs. PRTA: 63%
Market capitalization -- DNLI: $2.1B vs. PRTA: $322.42M
DNLI [@Biotechnology] is valued at $2.1B. PRTA’s [@Biotechnology] market capitalization is $322.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $114.49B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whilePRTA’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • PRTA’s FA Score: 0 green, 5 red.
According to our system of comparison, both DNLI and PRTA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 3 TA indicator(s) are bullish while PRTA’s TA Score has 4 bullish TA indicator(s).

  • DNLI’s TA Score: 3 bullish, 6 bearish.
  • PRTA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, PRTA is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а +2.56% price change this week, while PRTA (@Biotechnology) price change was +4.17% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.78%. For the same industry, the average monthly price growth was +31.36%, and the average quarterly price growth was +15.04%.

Reported Earning Dates

DNLI is expected to report earnings on Jul 31, 2025.

PRTA is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+1.78% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.1B) has a higher market cap than PRTA($322M). DNLI YTD gains are higher at: -29.097 vs. PRTA (-56.751). PRTA has higher annual earnings (EBITDA): -137.71M vs. DNLI (-505.16M). DNLI has more cash in the bank: 818M vs. PRTA (418M). PRTA has less debt than DNLI: PRTA (10.2M) vs DNLI (48.6M). PRTA has higher revenues than DNLI: PRTA (138M) vs DNLI (0).
DNLIPRTADNLI / PRTA
Capitalization2.1B322M652%
EBITDA-505.16M-137.71M367%
Gain YTD-29.097-56.75151%
P/E RatioN/AN/A-
Revenue0138M-
Total Cash818M418M196%
Total Debt48.6M10.2M476%
FUNDAMENTALS RATINGS
DNLI vs PRTA: Fundamental Ratings
DNLI
PRTA
OUTLOOK RATING
1..100
6212
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
56
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9494
PRICE GROWTH RATING
1..100
6194
P/E GROWTH RATING
1..100
9995
SEASONALITY SCORE
1..100
n/a31

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRTA's Valuation (56) in the Biotechnology industry is somewhat better than the same rating for DNLI (93). This means that PRTA’s stock grew somewhat faster than DNLI’s over the last 12 months.

PRTA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DNLI (100). This means that PRTA’s stock grew similarly to DNLI’s over the last 12 months.

PRTA's SMR Rating (94) in the Biotechnology industry is in the same range as DNLI (94). This means that PRTA’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's Price Growth Rating (61) in the Biotechnology industry is somewhat better than the same rating for PRTA (94). This means that DNLI’s stock grew somewhat faster than PRTA’s over the last 12 months.

PRTA's P/E Growth Rating (95) in the Biotechnology industry is in the same range as DNLI (99). This means that PRTA’s stock grew similarly to DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIPRTA
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
67%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
79%
MACD
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 3 days ago
75%
Declines
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 15 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HCMNX18.81N/A
N/A
HCM Dividend Sector Plus A
ANPRX28.61N/A
N/A
Virtus NFJ Mid-Cap Value R6
CLTAX15.75N/A
N/A
Catalyst/Lyons Tactical Allocation A
JHURX33.77N/A
N/A
JPMorgan Emerging Markets Equity R3
RVPHX8.28-0.06
-0.72%
Royce Smaller-Companies Growth Invmt

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with NRIX. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+0.35%
NRIX - DNLI
56%
Loosely correlated
-2.92%
BEAM - DNLI
56%
Loosely correlated
-2.27%
OCUL - DNLI
55%
Loosely correlated
+1.10%
RGNX - DNLI
55%
Loosely correlated
-0.23%
ARWR - DNLI
54%
Loosely correlated
-1.88%
More

PRTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRTA has been loosely correlated with RCKT. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if PRTA jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRTA
1D Price
Change %
PRTA100%
-1.32%
RCKT - PRTA
54%
Loosely correlated
-4.33%
SVRA - PRTA
46%
Loosely correlated
-3.95%
DNLI - PRTA
42%
Loosely correlated
+0.35%
KRYS - PRTA
39%
Loosely correlated
-0.81%
AXON - PRTA
38%
Loosely correlated
-1.16%
More